• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov12
Oppenheimer Analyst Maintains Buy Rating on Keros Therapeutics
13:02
Nov6
H.C. Wainwright Reiterates Buy Rating on Keros Therapeutics
11:51
Keros Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 14.26 M (forecast USD 4.222 M), actual EPS USD -0.18 (forecast USD -1.02)
04:00
Keros Therapeutics released FY2025 9 Months Earnings on November 5 (EST), actual revenue USD 243.68 M, actual EPS USD 2.68
04:00
Oct20
Keros Therapeutics Launches Stock Repurchase Program
14:02
Aug7
Keros Therapeutics released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 229.41 M, actual EPS USD 2.86
03:00

Schedules & Filings

Schedules
Filings
Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 14.26 M, Net Income -7.28 M, EPS -0.18

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 18.17 M, Net Income -30.7 M, EPS -0.7599

May6
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 211.25 M, Net Income 148.45 M, EPS 3.62

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More